177 Lu-DOTATATE Uptake in the Lungs of a Patient With COVID-19 Pneumonia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38968595.
- Also identified by DOI 10.1097/RLU.0000000000005324.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 76-year-old woman with liver and bone metastasis of a duodenal neuroendocrine tumor received peptide receptor radionuclide therapy with 177 Lu-DOTATATE. Scintigraphy with SPECT/CT performed 4 days after the treatment demonstrated 177 Lu-DOTATATE uptake as multifocal ground glass opacities in the bilateral lungs. This uptake was considered to be due to COVID-19 pneumonia because the patient was infected with the virus 7 days prior to the treatment. The lung opacities became smaller, showing a decreased uptake, 2 months later, after the second treatment. 177 Lu-DOTATATE may be taken up during the active phase of COVID-19 pneumonia.
Medical subject headings
- COVID-19
- Organometallic Compounds
- Lung
- Octreotide